EUVIMEDEUVIMED entdecken
Crossref

A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α

Chao Wang, Bin Xu, Lilan Xin iD, Zhangxiao Guo, Xiaofei Deng, Chune Dong, Jian Yang, Hai-Bing Zhou iD

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18182-18203

DOI: 10.1021/acs.jmedchem.6c00521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.07.2026. Verfasst von Chao Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan430071, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China (NSFC), Hubei Research Center of Fundamental Science-Chemistry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen receptor α (ERα) remains a pivotal therapeutic target for ER-positive (ER+) breast cancer, yet resistance to endocrine therapies driven by ligand-binding pocket (LBP) mutations demands novel strategies. To integrate the complementary strengths of binding modalities of the orthosteric LBP and the allosteric coactivator binding site (CBS) against endocrine resistance, we designed a series of ERα LBP/CBS dual-targeting proteolysis-targeting chimeras (PROTACs). The lead compound P5 demonstrated high binding affinities for LBP and CBS sites, potent antiproliferative activity, and efficient ERα degradation efficacy across a panel of breast cancer cell lines via the ubiquitin-proteasome system. Mechanistically, P5 triggered S-phase cell cycle arrest and apoptosis in LCC2 cells. In vivo, P5 exhibited significant tumor growth inhibition in the LCC2 xenograft model, with efficacy comparable to fulvestrant, and a favorable safety profile. Our findings validate the LBP/CBS dual-targeting PROTAC strategy as a promising avenue for overcoming resistance in ER+ breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaDrug Resistance, NeoplasmAntineoplastic AgentsHumansProteolysis Targeting ChimeraAnimalsFemaleCell Line, TumorCell ProliferationBreast NeoplasmsMiceApoptosisBinding SitesAllosteric RegulationProteolysisMice, Nude

Substanzen

Estrogen Receptor alphaProteolysis Targeting ChimeraAntineoplastic AgentsESR1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan430071, China.
  • Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan University, Wuhan430060, China.
  • Frontier Science Center for Immunology and Metabolism, State Key Laboratory of Virology and Biosafety, Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Dr…

ORCID-Profile: Lilan Xin, Hai-Bing Zhou

Förderung

  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China (NSFC)
  • Hubei Research Center of Fundamental Science-Chemistry

Zitieren

APA

Wang, C., Xu, B., Xin, L., Guo, Z., Deng, X., Dong, C., Yang, J., & Zhou, H. B. (2026). A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α. Journal of Medicinal Chemistry, 69(15), 18182-18203. https://doi.org/10.1021/acs.jmedchem.6c00521

Vancouver

Wang C, Xu B, Xin L, Guo Z, Deng X, Dong C, et al. A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α. Journal of Medicinal Chemistry. 2026;69(15):18182-18203. doi:10.1021/acs.jmedchem.6c00521

BibTeX
@article{Wang2026,
  author = {Wang, Chao and Xu, Bin and Xin, Lilan and Guo, Zhangxiao and Deng, Xiaofei and Dong, Chune and Yang, Jian and Zhou, Hai-Bing},
  title = {A Novel Dual-Targeting PROTAC Overcomes Endocrine Resistance by Engaging Orthosteric and Allosteric Sites of Estrogen Receptor α},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {18182--18203},
  doi = {10.1021/acs.jmedchem.6c00521}
}
Kostenlos starten →